Virtual Conference on retroviruses and opportunistic infections (CROI) held on February 22-24, 2022

  1. Han WM, Apornpong T, Ubolyam S, Ker SJ, Avihingsanon A. Metabolic Associated Fatty Liver Disease and its Association with Epicardial Fat (Poster)
  2. Han WM, Apornpong T, Gatechompol S, Ubolyam S, Kerr SJ, Erlandson K. Association of phenotypic aging with comorbidities, Farilty and Inflammatory Marker. (Poster)
  3. Tan S, Thanprasertsuk S, Thongsawat S, Salvadori N, Menetrey C, STORM-C-1 Research Team. Efficacy & Safety of Ravidasvir + Sofosbuvir in Hepatitis C: STROM-C-1 Final Results. (Poster)
  4. Singh KP, Zerbato J, Zhao W, Wong DK, Cloherty G, Gersch J, Mason H, Rhodes A, Revill P, Avihingsanon A, Audsley J, Yuen M, Lewin S. Hepatitis B RNA and Core-related Antigen in HIV-HBV Coinfection. (poster)
  5. Chattranukulchai P, Siwamogsatham S, Lwin HMS, Apornpong T, Han WM, Gatechompol S, Putcharoen O, Avihingsanon A. High-sensitive Troponins and Coronary Calcium Score in Older Asian HIV. (poster)
  6. Janekrongtham C, Lolekha R, Avihingsanon A, Ariyothai N, Luengwattanapong R, Mookleemas P, Kittinunvorakoon C, Sethaputra C, Jirajariyavej S, Ubolyam S, Fujitnirun C, Watcharasuwanseree S, Ayuthaya TPN, Northbrook S, Lertpiriyasuwat C. Potential Use of Urine LF-LAM in Diagnosing Active TB in Thai HIV-Positive Adults (poster)

A5324 study

Letendre SL, Roa J, Chen H, McKhann A, Marra CM, Daar ES, Hunt PW, Campbell T, Swaminathan S, Ha B, Alston-Smith B, Paul R, Spudich SS. ACTG A5324: A randomized trial of ART intensification for cognitive impairment in PWH (poster)

A5332 study

  1. Weir IR, Overton ET, Zanni MV, Fischinger S, Fitch K, Aberg JA, Fichtenbaum CJ, Bloomfield GS, Malvestutto C, McCallum S, Douglas PS, Alter G, Ribaudo HJ, Grinspoon S. Asymptomatic SARS-CoV-2 Infection is Extremely Common Among People with HIV (poster)
  2. Erlandson K, Fitch K, McCallum S, Ribaudo HJ, Overton ET, Bloomfield GS, Brown T, Fichtenbaum CJ, Bares S, Aberg JA, Douglas PS, Moran L, Mave V, Grinspoon S. Geographical Differences in Functional Impairment of People with HIV. (oral presentation)
  3. Fulda ES, Fitch K, Overton ET, Zanni MV, Aberg JA, Currier JS, Lu MT, Malvestutto C, Fichtenbaum CJ, Martinez E, Umbleja T, Douglas PS, Fibaudo HJ, Grinspoon S. COVID-19 Vaccination rates in a Global HIV Cohort. (oral presentation)
  4. Fichtenbaum CJ, Ribaudo HJ, Taron J, Leon-Cruz JT, Utay NS, Ho K, Luetkemeyer A, Swaminathan S, Johnston C, Fulda ES, Kileel E, Lu MT, Grinspoon S, Lake J. NAFLD is Common and Associated with Cardiovascular Risk in REPRIEVE Participants. (poster)
  5. Zanni MV, Foldyna B, Williams K, Burdo TH, McCallum S, Looby SE, Autissier P, Fitch K, Currier JS, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon S. Subclinical Atherosclerosis and Immune Activation Among US Females Vs Males with HIV. (poster)
  6. Overton ET, Kantor A, Fitch K, Muntner PM, Mosepele M, Aberg JA, Fichtenbaum CJ, McComsey GA, Malvestutto C, Lu MT, Doublas PS, Grinspoon S, Ribaudo HJ, Wyatt C. Proteinuria is Common Among People with HIV with Controlled HIV Viremia. (poster)

A5345 study

Li J, Kittilson A, Melbergh M, Wonderlich ER, Kinslow J, Aga E, Bosch RJ, Coombs R, Deeks SG, Gandhi RT, Busch MP, Landay A, Macatangay BJ, Smith DM. Size and Activity of the HIV Reservoir Predict Rebound Timing after ART Interruption. (Poster)

A5354 study

  1. Daar ES, Ritz J, Zheng L, Ananworanich J, Kanyama C, Little SJ, Cohn SE, Riddler SA, Collier AC, Coombs R, Fox L, Lama JR, Crowell TA. Feasibility and Viral Response to Treating Acute/Early HIV in a Multinational Study. (Poster)
  2. Sieg SF, Puleo JA, Zheng L, Clagett B, Lama JR, Fox L, Ananworanich J, Ruxrungtham K, Grinszteign B, Arduino RC, Eron JJ, Mellors JW, Daar ES, Crowell TA. HIV-Specific T-Cell Frequencies and Function After ART During Acute or Early HIV. (Poster)
  3. Veen LV, Moldt B, Selzer L, Li J, Parvangada PC, Ananworanich J, Crowell TA, Eron JJ, Daar ES, Haubrich RH, Geleziunas R, Cyktor J, Mellors JW, Callebaut C. HIV Envelope Diversity and Sensivity to bNAbs Across Stages of Acute and Early HIV. (Poster)
  4. Crowell TA, Ritz J, Zheng L, Naqvi A, Cyktor J, Sieg SF, Lama JR, Rooney JF, Fox L, Ananworanich J, Eron JJ, Zyl GV, Mellors JW, Daar ES. Early antiretroviral therapy reduces but does not eliminate HIV DNA in blood. (Poster)

A5360 study

Sowah L, Smeaton LM, Brates I, Bhattacharya D, Linas B, Kreter B, Wagner-Cardoso S, Solomon SS, Sulkowski MS, Robbins GK. Adherence in the ACTG A5360 HCV Minimal Monitoring (MINMON) Trial.(poster)

A5372 study

Imperial MZ, Luetkemeyer A, Dawson R, Cramer Y, Rosenkranz S, Swindells S, Gelmanova I, Avihingsanon A, Arduino RC, Samaneka W, Dooley K, Savic R, Podany AT. DTG PK in people with HIV receiving daily 1HP for latent TB treatment. (oral presentation)

A5375 study

Mngqibisa R, Smeaton LM, Olefsky M, Podany AT, Barr E, Belaunzaran P, Badal-Faesen S, Kachale E, Kanyama C, Schalkwyk MV, Woolley E, Cohn SE, Godfrey C, Scarsi KK. PK of dose-adjusted emergency contraception with rifampicin therapy in ACTG A5375. (oral presentation)